Keywords:
Pharmacodynamic models; Weight loss; Early phase clinical trials; Obesity
Abstract:
Early-phase clinical trials for anti-obesity drugs are often too short to observe significant weight loss, necessitating surrogate markers of efficacy. This white paper identifies key pharmacodynamic (PD) biomarkers that can bridge this gap. A narrative review highlighted five PD methodologies: blood ketone levels, indirect calorimetry metrics, laboratory eating behavior monitoring, gut hormone responses, and body composition analyses. Each method taps into a physiological mechanism such as fat oxidation, energy expenditure, appetite regulation, hormonal satiety signals, or fat mass reduction that manifests before appreciable weight change. Integrating these PD markers into Phase I/II trials could enable drug developers to gauge efficacy earlier. This approach may accelerate go/no-go decisions and reduce time to proof-of-concept. A structured implementation of early PD endpoints can demonstrate early onset of pharmacologic activity, offering timely evidence of efficacy that may support more informed development decisions and enable greater scientific and operational efficiency.